ABBV vs PFE
By Alex · Tickerpine
AbbVie Inc. vs Pfizer, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | PFE |
|---|---|---|
| Price | $248.76 | $26.31 |
| Market cap | $439.59B | $149.96B |
| P/E ratio | 70.5 | 35.1 |
| ROE | — | 5.01% |
| Profit margin | 9.80% | 6.80% |
| Revenue growth | 10.20% | 2.60% |
| Dividend yield | 2.77% | 6.46% |
| Beta | 0.28 | 0.28 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs PFE in plain English
- ABBV is the bigger company — about 2.9× the market cap of PFE.
- PFE is cheaper on earnings (P/E 35.1 vs 70.5).
- ABBV is growing revenue faster (10% vs 3%).
- PFE has the higher dividend yield (6.46% vs 2.77%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
PFE return calculator
See what $1,000 in Pfizer, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.